Dianthus Therapeutics Inc. (DNTH) Stock Analysis

Dianthus Therapeutics Inc. (DNTH) is a publicly traded company in the HEALTHCARE sector. It trades at $81.57, carries a market capitalization of $4.89B. This page summarizes the public market data, fundamentals, and frequently asked questions for DNTH, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $81.57
• Market Cap: $4.89B
• EPS: $-4.23
• 52-Week High: $96.50
• 52-Week Low: $16.64

Market Sentiment

Dianthus Therapeutics Inc. currently has a Neutral sentiment score of 0.03.

About Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York dedicated to developing novel monoclonal antibody therapies for severe autoimmune and inflammatory diseases. The firm boasts a strong pipeline aimed at addressing significant unmet medical needs through its proprietary drug development programs. By advancing innovative solutions and progressing through critical clinical trials, Dianthus is positioning itself at the forefront of precision medicine, making i...

GNG Research Analysis

GNG Research scores Dianthus Therapeutics Inc. (DNTH) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DNTH.

Frequently Asked Questions

Does DNTH pay dividends?

Dianthus Therapeutics Inc. (DNTH) does not currently pay a regular dividend.

What is DNTH's market cap?

Dianthus Therapeutics Inc. (DNTH) has a market capitalization of $4.89B with a current stock price of $81.57.